Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index; 11 of the 30 sources its claims cite were checked for support.

Native metabolomics identifies the rivulariapeptolide family of protease inhibitors

Open access
Reher, Raphael, Aron, Allegra T., Fajtová, Pavla, Stincone, Paolo, Wagner, Berenike, Pérez-Lorente, Alicia I., Liu, Chenxi, Shalom, Ido Y. Ben, Bittremieux, Wout, Wang, Mingxun, Jeong, Kyowon, Matos-Hernandez, Marie L., Alexander, Kelsey L., Caro-Diaz, Eduardo J., Naman, C. Benjamin, Scanlan, J. H. William, Hochban, Phil M. M., Diederich, Wibke E., Molina-Santiago, Carlos, Romero, Diego, Selim, Khaled A., Sass, Peter, Brötz-Oesterhelt, Heike, Hughes, Chambers C., Dorrestein, Pieter C., O’Donoghue, Anthony J., Gerwick, William H., Petras, Daniel · 2022 · Nature Communications

Published version of a preprint

Abstract

The identity and biological activity of most metabolites still remain unknown. A bottleneck in the exploration of metabolite structures and pharmaceutical activities is the compound purification needed for bioactivity assignments and downstream structure elucidation. To enable bioactivity-focused compound identification from complex mixtures, we develop a scalable native metabolomics approach that integrates non-targeted liquid chromatography tandem mass spectrometry and detection of protein binding via native mass spectrometry. A native metabolomics screen for protease inhibitors from an environmental cyanobacteria community reveals 30 chymotrypsin-binding cyclodepsipeptides. Guided by the native metabolomics results, we select and purify five of these compounds for full structure elucidation via tandem mass spectrometry, chemical derivatization, and nuclear magnetic resonance spectroscopy as well as evaluation of their biological activities. These results identify rivulariapeptolides as a family of serine protease inhibitors with nanomolar potency, highlighting native metabolomics as a promising approach for drug discovery, chemical ecology, and chemical biology studies.

Overview

CoChat Summary

## TL;DR

The paper develops a “native metabolomics” workflow that combines LC-MS/MS with native MS protein-infused screening to find metabolites that bind a target protein directly from crude extracts. Applied to a marine cyanobacterial extract, it identified 30 chymotrypsin-binding cyclodepsipeptides and led to the discovery of the rivulariapeptolides as nanomolar serine protease inhibitors.

## Key findings

  • A single 10-min LC-MS run of a Rivularia sp. cyanobacterial extract revealed more than 30 potential small molecule–protein complexes and 30 chymotrypsin-binding natural products.
  • The workflow enabled isolation and structure elucidation of five compounds plus one derivative: rivulariapeptolides 1185, 1155, 1121, 989 and molassamide B.
  • The purified compounds were confirmed as nanomolar chymotrypsin inhibitors; compound 1 (rivulariapeptolide 1185) was most potent against chymotrypsin with IC50 = 13.17 nM.
  • A single ortho-bromination in the N-methyltyrosine moiety produced a 35-fold increase in potency for molassamide B (6) versus molassamide (5) against chymotrypsin (24.65 nM vs 862.60 nM); the paper also reports IC50 = 4.94 nM for compound 2 against elastase and IC50 = 5.42 nM for compound 6 against proteinase K.

## Methods

  • Developed a native metabolomics workflow that pairs non-targeted LC-MS/MS with post-column protein infusion and native MS detection of protein-ligand complexes; the target protein was chymotrypsin.
  • Screened a methanolic crude extract from an environmental cyanobacterial biofilm of Rivularia sp. collected in Puerto Rico; features were matched between native MS and metabolomics data by retention time and mass offset.
  • Followed up by fractionation, preparative/semi-preparative HPLC, MS/MS, chemical derivatization, NMR, and fluorescence-based protease inhibition assays to determine structures and IC50 values.
  • Data analysis used Xtract/FLASHDeconv, MZmine2.37, GNPS feature-based molecular networking, SIRIUS/ZODIAC, and CANOPUS.

## Limitations

  • The authors state that the approach was used mainly as a first hypothesis-generating tool and that putative binders should be validated with orthogonal methods; absolute binding affinities and enzyme inhibition rates were not determined by native metabolomics alone.
  • They note that the method’s suitability for lower-affinity protein-small molecule interactions and larger proteins remains to be characterized.
  • Evident from the text: the workflow required careful optimization of buffer and instrument settings, and the paper relies on a single environmental sample/case study, so generality beyond the demonstrated system is not established.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41467-022-32016-6

Cites

78 of 78 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Overview of the native metabolomics workflow. a Native metabolomics setup. A crude extract is separated by µ-flow UHPLC. The pH is adjusted after chromatography with ammonium acetate to native-like conditions via the make-up pump. Orthogonally, the protein of interest is infused, and the resulting protein-binder complexes are measured by MS. The procedure is repeated as a metabolomics run (high-resolution UHPLC-MS/MS acquisition without protein infusion). For the data analysis (b) the Δ m/z and retention time of the native MS run are correlated with m/z values and retention time of the metabolomics (LC-MS/MS) run and subsequently visualized using molecular networking and retention time pairing that links the observed mass differences of the protein in the native state vs bound states with the parent mass of MS/MS spectra of the small molecule.
Fig. 1 Overview of the native metabolomics workflow. a Native metabolomics setup. A crude extract is separated by µ-flow UHPLC. The pH is adjusted after chromatography with ammonium acetate to native-like conditions via the make-up pump. Orthogonally, the protein of interest is infused, and the resulting protein-binder complexes are measured by MS. The procedure is repeated as a metabolomics run (high-resolution UHPLC-MS/MS acquisition without protein infusion). For the data analysis (b) the Δ m/z and retention time of the native MS run are correlated with m/z values and retention time of the metabolomics (LC-MS/MS) run and subsequently visualized using molecular networking and retention time pairing that links the observed mass differences of the protein in the native state vs bound states with the parent mass of MS/MS spectra of the small molecule.CC BY · PubMed Central
Fig. 2 Native metabolomics analysis. a Left panel: Total ion chromatogram (m/z 300–2000) of cyanobacterial crude extract and blank. The retention times (RT = 4.5–5.5 min) of major Ahp-cyclodepsipeptides are highlighted. Right panel: Deconvoluted extracted ion chromatogram (m/z 25,233 ± 5) of alpha-chymotrypsin screened against the cyanobacterial crude extract under native MS conditions and negative control. Acetonitrile (ACN) concentration on column and post-column (including make-up) are shown as dashed lines. The ACN concentrations are given at the pump for a given time, and a ~ 2 min delay time between pump and column has to be taken into account. b Correlation molecular network of deconvoluted chymotrypsin and putatively new small molecule inhibitors binders by native MS (A larger version of the network with detailed precursor mass labels of all nodes is available in the supporting information Supplementary Fig. 3). c Upper left panel: Extracted ion chromatogram (m/z 1,186.6284–1,186.6522) of putative chymotrypsin-binder rivulariapeptolide 1185 at RT = 5.5 min. Middle and upper right panel: Multiple charged and deconvoluted MS spectra and extracted ion chromatogram (m/z 26,420 ± 5) of a putative chymotrypsin-binder complex. The mass difference between the putative chymotrypsin-binder complex (m/z 26,420 ± 5) and apo-chymotrypsin (25,233 ± 5) suggests a molecular weight of 1187 ± 5 Da for the putative chymotrypsin-binder rivulariapeptolide 1185. Lower left panel: Extracted ion chromatogram (m/z 1,156.5819–1,156.6051) of putative chymotrypsin-binder rivulariapeptolide 1185 at RT = 5.1 min. Middle and lower right panel: Multiple charged and deconvoluted MS spectra Extracted ion chromatogram (m/z 26,385 ± 5) of a putative chymotrypsin-binder complex. Mass difference between the putative chymotrypsin-binder complex (m/z 26,385 ± 5) and apo-chymotrypsin (25,233 ± 5) suggests a molecular weight of 1152 ± 5 Da for the putative chymotrypsin-binder rivulariapeptolide 1155. (A larger version of mass spectra is shown in the supporting information Supplementary Fig. 5).
Fig. 2 Native metabolomics analysis. a Left panel: Total ion chromatogram (m/z 300–2000) of cyanobacterial crude extract and blank. The retention times (RT = 4.5–5.5 min) of major Ahp-cyclodepsipeptides are highlighted. Right panel: Deconvoluted extracted ion chromatogram (m/z 25,233 ± 5) of alpha-chymotrypsin screened against the cyanobacterial crude extract under native MS conditions and negative control. Acetonitrile (ACN) concentration on column and post-column (including make-up) are shown as dashed lines. The ACN concentrations are given at the pump for a given time, and a ~ 2 min delay time between pump and column has to be taken into account. b Correlation molecular network of deconvoluted chymotrypsin and putatively new small molecule inhibitors binders by native MS (A larger version of the network with detailed precursor mass labels of all nodes is available in the supporting information Supplementary Fig. 3). c Upper left panel: Extracted ion chromatogram (m/z 1,186.6284–1,186.6522) of putative chymotrypsin-binder rivulariapeptolide 1185 at RT = 5.5 min. Middle and upper right panel: Multiple charged and deconvoluted MS spectra and extracted ion chromatogram (m/z 26,420 ± 5) of a putative chymotrypsin-binder complex. The mass difference between the putative chymotrypsin-binder complex (m/z 26,420 ± 5) and apo-chymotrypsin (25,233 ± 5) suggests a molecular weight of 1187 ± 5 Da for the putative chymotrypsin-binder rivulariapeptolide 1185. Lower left panel: Extracted ion chromatogram (m/z 1,156.5819–1,156.6051) of putative chymotrypsin-binder rivulariapeptolide 1185 at RT = 5.1 min. Middle and lower right panel: Multiple charged and deconvoluted MS spectra Extracted ion chromatogram (m/z 26,385 ± 5) of a putative chymotrypsin-binder complex. Mass difference between the putative chymotrypsin-binder complex (m/z 26,385 ± 5) and apo-chymotrypsin (25,233 ± 5) suggests a molecular weight of 1152 ± 5 Da for the putative chymotrypsin-binder rivulariapeptolide 1155. (A larger version of mass spectra is shown in the supporting information Supplementary Fig. 5).CC BY · PubMed Central
Fig. 3 Structure elucidation workflow based on NMR and MS/MS data. a The workflow combined automated in-silico MS/MS and NMR annotation tools for fast compound class identification and dereplication of known natural products exemplified by the new natural product rivulariapeptolide 1185. b Molecular networking and SMART analysis suggested the presence of an Ahp-cyclodepsipeptide molecular family. c In-depth MS and MS/MS analysis of the new natural products with SIRIUS helped to establish the molecular formula and substructural information about the characteristic N-acylated proline residues. d Unambiguous structure elucidation by various 1D/2D NMR and MS/MS experiments led to the planar structure of rivulariapeptolide 1185. Selected 2D NMR-derived correlations and MS² fragmentations are depicted. The distinctive structural moieties are highlighted in blue bubbles and are described in the associated blue captions of panels b–d. Residues (R1–R4) highlighted in red represent unknown structural elements at the current analysis stage in panels b–d.
Fig. 3 Structure elucidation workflow based on NMR and MS/MS data. a The workflow combined automated in-silico MS/MS and NMR annotation tools for fast compound class identification and dereplication of known natural products exemplified by the new natural product rivulariapeptolide 1185. b Molecular networking and SMART analysis suggested the presence of an Ahp-cyclodepsipeptide molecular family. c In-depth MS and MS/MS analysis of the new natural products with SIRIUS helped to establish the molecular formula and substructural information about the characteristic N-acylated proline residues. d Unambiguous structure elucidation by various 1D/2D NMR and MS/MS experiments led to the planar structure of rivulariapeptolide 1185. Selected 2D NMR-derived correlations and MS² fragmentations are depicted. The distinctive structural moieties are highlighted in blue bubbles and are described in the associated blue captions of panels b–d. Residues (R1–R4) highlighted in red represent unknown structural elements at the current analysis stage in panels b–d.CC BY · PubMed Central
Fig. 4 Structure-activity relationships of rivulariapeptolides and molassamides. a Structures of the isolated rivulariapeptolides 1185 (1), 1155 (2), 1121 (3), 988 (4); red = residues defined in panel c. b Structures of the isolated known molassamide (5), and the new molassamide B (6). c Potency of isolated compounds for selected serine proteases following 40 min pre-incubations. Data were presented as the mean ± SD, n = 3. Ba butyric acid, Pro proline. Source data are provided as a Source Data file.
Fig. 4 Structure-activity relationships of rivulariapeptolides and molassamides. a Structures of the isolated rivulariapeptolides 1185 (1), 1155 (2), 1121 (3), 988 (4); red = residues defined in panel c. b Structures of the isolated known molassamide (5), and the new molassamide B (6). c Potency of isolated compounds for selected serine proteases following 40 min pre-incubations. Data were presented as the mean ± SD, n = 3. Ba butyric acid, Pro proline. Source data are provided as a Source Data file.CC BY · PubMed Central

Verification

Claims the paper makes

10 Valid · 3 Not valid · 4 Not checked · 61 Own results and interpretations

34 more claims

Create a free account to see all 78 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 19
  • It may state two separate claims as one. 22
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 72 references

Research works printed but not linked: 1

  1. Anderson, J., Schiffer, C., Lee, S.-K. & Swanstrom, R. in Antiviral Strategies (eds. Kräusslich, H.-G. & Bartenschlager, R.) (Springer, 2009).

Cited by

See all 53

Metadata

Authors
Reher, R., Aron, A. T., Fajtová, P., Stincone, P., Wagner, B., Pérez-Lorente, A. I., Liu, C., Shalom, I. Y. B., Bittremieux, W., Wang, M., Jeong, K., Matos-Hernandez, M. L., Alexander, K. L., Caro-Diaz, E. J., Naman, C. B., Scanlan, J. H. W., Hochban, P. M. M., Diederich, W. E., Molina-Santiago, C., Romero, D., Selim, K. A., Sass, P., Brötz-Oesterhelt, H., Hughes, C. C., Dorrestein, P. C., O’Donoghue, A. J., Gerwick, W. H., & Petras, D.
Affiliations
  • Scripps Institution of Oceanography (US)
  • University of California San Diego (US)
  • University of Tübingen (DE)
  • Ningbo University (CN)
  • Philipps University of Marburg (DE)
  • Consejo Superior de Investigaciones Científicas (ES)
  • German Center for Infection Research (DE)
Corresponding author
  • Gerwick, William H.
  • Petras, Daniel
Venue
Nature Communications
Published
2022-08-08
Volume
13
Issue
1
Pages
4619-4619
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4290648675
Cited by
53
References
72
Citations by year
2026: 5 · 2025: 18 · 2024: 11 · 2023: 15 · 2022: 3
FWCI
7.03
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DIGITAL.CSIC (Spanish National Research Council (CSIC)) (acceptedVersion, other-oa)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
Funders
Deutsche Forschungsgemeinschaft (EXC 2124)
Topics
  • Life Sciences › Immunology and Microbiology › Applied Microbiology and Biotechnology › Microbial Natural Products and Biosynthesis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolomics and Mass Spectrometry Studies
  • Physical Sciences › Chemistry › Spectroscopy › Mass Spectrometry Techniques and Applications
Keywords
protease inhibitors, serine protease inhibitors, cyclodepsipeptides, native mass spectrometry, cyanobacteria, compound purification, structure elucidation, chemical ecology, drug discovery
MeSH terms
Chromatography, Liquid, Magnetic Resonance Spectroscopy, Protease Inhibitors, Tandem Mass Spectrometry, Metabolomics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Native metabolomics identifies the rivulariapeptolide family of protease inhibitors. https://app.cochat.ai/papers/10.1038/s41467-022-32016-6
The paper
Reher, R., Aron, A. T., Fajtová, P., Stincone, P., Wagner, B., Pérez-Lorente, A. I., Liu, C., Shalom, I. Y. B., Bittremieux, W., Wang, M., Jeong, K., Matos-Hernandez, M. L., Alexander, K. L., Caro-Diaz, E. J., Naman, C. B., Scanlan, J. H. W., Hochban, P. M. M., Diederich, W. E., Molina-Santiago, C., . . . Petras, D. (2022). Native metabolomics identifies the rivulariapeptolide family of protease inhibitors. Nature Communications. https://doi.org/10.1038/s41467-022-32016-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.